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Development/Plasticity/Repair
Amyloid Precursor Protein Cleavage-Dependent and
-Independent Axonal Degeneration Programs Share a
Common Nicotinamide Mononucleotide Adenylyltransferase
1-Sensitive Pathway
Bhupinder P. S. Vohra,1,4* Yo Sasaki,1* Bradley R. Miller,2 Jufang Chang,1 Aaron DiAntonio,2,3 and Jeffrey Milbrandt1,3
Departments of 1Genetics and 2Developmental Biology, and 3HOPE Center for Neurological Disorders, Washington University School of Medicine, St. Louis,
Missouri 63110, and 4Biology Department, University of Central Arkansas, Conway, Arkansas 72034
Axonal degeneration is a hallmark of many debilitating neurological disorders and is thought to be regulated by mechanisms distinct
from those governing cell body death. Recently, caspase 6 activation via amyloid precursor protein (APP) cleavage and activation of DR6
was discovered to induce axon degeneration after NGF withdrawal. We tested whether this pathway is involved in axonal degeneration
caused by withdrawal of other trophic support, axotomy or vincristine exposure. Neurturin deprivation, like NGF withdrawal activated
this APP/DR6/caspase 6 pathway and resulted in axonal degeneration, however, APP cleavage and caspase 6 activationwere not involved
in axonal degeneration induced by mechanical or toxic insults. However, loss of surface APP (sAPP) and caspase 6 activation were
observed during axonal degeneration induced by dynactin 1(Dctn1) dysfunction, which disrupts axonal transport. Mutations in Dctn1
are associated with motor neuron disease and frontal temporal dementia, thus suggesting that the APP/caspase 6 pathway could be
important in specific types of disease-associated axonal degeneration. The NGF deprivation paradigm, with its defined molecular path-
way, was used to examine the context of Nmnat-mediated axonal protection.We found that althoughNmnat blocks axonal degeneration
after trophic factorwithdrawal, it didnot prevent loss of axon sAPPor caspase 6 activationwithin the axon, suggesting it acts downstream
of caspase 6. These results indicate that diverse insults induce axonal degeneration via multiple pathways and that these degeneration
signals converge on a common, Nmnat-sensitive program that is uniquely involved in axonal, but not cell body, degeneration.
Introduction
Why is axonal degeneration a common element of a diverse set of
neurological disorders? A favorite hypothesis is that a wide range
of neuronal insults triggers a general axonal self-destruction pro-
gram. In support of this hypothesis, overexpression of Wlds, or
its component Nmnat, blocks degeneration in response to many
distinct stimuli (Mack et al., 2001; Ferri et al., 2003; Araki et al.,
2004; Sasaki et al., 2006, 2009a,b; Yahata et al., 2009). The intrin-
sic pathways that drive degeneration are poorly understood,
however calcium influx, regulated protein degradation, and JNK
activation by DLK have all been implicated (Coleman, 2005; Luo
and O’Leary, 2005; Miller et al., 2009).
A general molecular pathway leading from the initial insult to
the effectors of axonal breakdown has remained elusive. Al-
though axonal destruction shares morphological features with
apoptosis, most studies indicate that it is a caspase-independent
process as manipulation of themitochondrial apoptotic machin-
ery or caspase inhibitors fail to block axonal degeneration (Sagot
et al., 1995; Finn et al., 2000; Watts et al., 2003; Whitmore et al.,
2003). Recently, however a candidate pathway for axonal degen-
eration following NGF withdrawal that involves activation of
caspase 6 was identified (Nikolaev et al., 2009). In this paradigm,
removal of nerve growth factor (NGF) initiates a cascade of
events whereby axonal APP is cleaved and the shed N-terminal
APP fragment activates the tumor necrosis factor (TNF) receptor
DR6. The activation of DR6 leads to caspase 6 activation and
eventual axonal destruction.
Defects in axonal transport and insufficient trophic support
are thought to be involved in many neurological disorders (De
Vos et al., 2008). Dctn1 is a component of the dynactin complex
that interacts with dynein to facilitate retrograde transport of
cargoes from the axon terminal to the neuronal cell body. Mis-
sensemutations inDCTN1, which encodes dynactin 1, are linked
to slowly progressing motor neuron diseases, ALS, ALS with
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FTD, and Perry syndrome (Puls et al.,
2003, 2005; Mu¨nch et al., 2004, 2005;
Wider and Wszolek, 2008; Farrer et al.,
2009; Vilarin˜o-Gu¨ell et al., 2009). Patients
with these mutations also manifest mild
sensory neuropathy (Puls et al., 2005).
Mutation of DCTN1 is thought to cause
neuronal dysfunction via disruption of
retrograde axonal transport that results in
decreased availability of trophic factors in
the cell body. Because of the potential in-
volvement in trophic factor deprivation,
we hypothesized that the APP/DR6/
caspase 6 pathway could play a role in
neurological disorders caused by defective
axonal transport. Furthermore, this path-
way could also be involved in axonal de-
generation due to mechanical injury, as
blocking APP cleavage reduces axonal de-
generation, neuronal loss and cognitive
deficits resulting from traumatic brain in-
jury (Loane et al., 2009). The identifica-
tion of this APP-dependent pathway is an
important advance in our understanding
of themechanism of axonal degeneration,
however it remains unclear whether APP
processing is a common initiating step in
axonal degeneration or instead in one of
multiple stimulus-dependent axonal de-
generation programs (for review, see Kim
and Tsai, 2009; Wiedemann, 2009).
Materials andMethods
Reagents. The following primary antibodies
were used: Anti-amyloid precursor protein (1:
100; MAB348, Millipore), Active Caspase-6
Polyclonal Antibody (1:100, BioVision), anti-
N-APP polyclonal antibody (20 g/ml, Fisher
Scientific), Neurofilament mouse monoclonal
(1:1000, Sigma-Aldrich). The secondary anti-
bodies used were Alexa Fluor 488- and 594-
conjugated anti-mouse and anti-rabbit antibodies
(1:500; Invitrogen). BACE inhibitor (10 M;
OM99-2) and cell-permeable caspase 6 inhibi-
tor (VEID-CHO) were purchased fromCalbiochem. The Apo Logix car-
boxyfluorescein caspase 6 detection kit was purchased from Cell
Technology Inc. All other reagents were from Sigma-Aldrich unless oth-
erwise noted.
Culture of SCG and DRGs. Tissue culture plates were coated with
poly-D-lysine and laminin (Invitrogen) and neurons were cultured as
previously described (Sasaki et al., 2009a). Briefly, DRGs were col-
lected from CD1 mouse (Charles River) embryos at embryonic day
12.5, whereas SCGs were collected from P0 Pups. DRGs were treated
with 0.05% trypsin and 0.02% EDTA at 37°C for 15 min. SCGs were
dissociated with collagenase (1 mg/ml) at 37°C for 30 min which was
followed by trypsinization for 15 min at 37°C. After dissociation,
DRGs and SCGs were triturated by passing repeatedly through a 1 ml
pipette tip and resuspended in 500 l of Neurobasal medium (In-
vitrogen) containing 0.2% B27 (Invitrogen) and 50 ng/ml NGF (2.5S;
Harlan Bioproducts). After brief centrifugation (2000  g), the cell
pellet was resuspended in 50 l of complete medium and neurons
were plated using drop culture method by placing (2 l) of cell sus-
pension slightly below the center of each 24 well and incubated at
37°C with 5% CO2 for 1 h. After cell attachment, 500 l of complete
medium containing 1 M 5-fluoro-2-deoxyuridine, and 1 M uridine
was added to each well.
Lentivirus-mediated gene knockdown. Oligonucleotides were designed
to target proteins using parameters set by Genescript on its siRNA design
website (Genescript) (Wang and Mu, 2004). Fifty-nine base pair oligo-
nucleotides were engineered containing both forward and reverse se-
quences for the 19 bp siRNA target sequences linked together with a
hairpin loop, and ligated into AgeI-BamHI cut pFUHIV downstream of
the U6 promoter (Chen et al., 2006). The lentiviral-expressing siRNAs
were produced and the efficiency of knockdownwas ascertained bymea-
suring the Dctn1mRNA levels. The target sequences used were siRNA #1
GCAGTGTGGACGTGTATAA, siRNA #2 GAAGATCCGAAGGCG-
GATG and siRNA #3 CCAGAGACTTTTGATTTCA.
Construction of lentiviral expression plasmids. mCherry was obtained
from Dr. Roger Tsien (University of California, San Diego, La Jolla, CA)
(Sharner et al., 2004). The cytNmnat1-mCherry fusion gene and Bcl-xl
cDNA (kindly provided by S. J. Weintraub, Washington University, St. Louis,
MO)were cloned into a lentiviral expressionplasmid (Lois et al., 2004).
Trophic factor deprivation. For NGF withdrawal experiments, SCG
neurons were grown in NGF-containing medium (50 ng/ml) cultured
for 5 d in vitro (DIV5). The NGF-containing medium was removed
and neurons were washed with NGF-depleted medium twice. Neu-
rons were then grown in NGF-depleted neurobasal/B27 medium con-
taining goat anti-NGF antibody (1:1000). For Neurturin deprivation
Figure 1. Distinct pathways of axonal degeneration activated by trophic factor deprivation, axotomy and vincristine intoxica-
tion. A, Dorsal root ganglia (DRG) were cultured for 5 d and axonal degeneration was induced by NGF withdrawal [NGF (-)],
axotomy or vincristine. Treatment with the BACE inhibitor (BACEi; OM99-2), which inhibits APP cleavage, or anti-N-terminal
APP-blocking antibody (ab N-APP) blocked axonal degeneration caused by NGF withdrawal, but not degeneration caused by
axotomy or vincristine. Similarly, caspase 6 inhibitor (Caspase 6i; zVEID-FMK) and overexpression of Bcl-xl delayed axonal degen-
eration caused by NGF deprivation only. In contrast, expression of cytNmnat1 prevented axonal degeneration in all paradigms
tested.B–D, Image analysis softwarewasused toprovide aquantitative analysis of axonal degeneration (i.e., degeneration index)
after NGF deprivation (B), axotomy (C), and vincristine administration (D). These analyses highlight the fact that BACE inhibitor,
N-APP-blocking antibody, caspase 6 inhibitor and Bcl-xl only block axonal degeneration stimulated by NGF withdrawal, whereas
cytNmnat1 protected axons after all insults tested. Degeneration indices before treatment insults are indicated as 0 h. Significantly
different (*p 0.001, Student’s t test) from neurons at time 0 (0 h NGF withdrawal).
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experiments, SCG neurons were established and grown for 2 d in
NGF-containingmedium. The neurons were washed with Neurobasal
medium containing 0.2% B27 to remove NGF and then cultured in
Neurobasal medium containing 0.2% B27 and Neurturin (40 ng/ml).
After 3 d, the neurons were washed twice with neurobasal containing
0.2% B27 without Neurturin and then cultured in Neurturin-free
medium.
Inhibitor and APP-blocking antibody treatment. In all the experiments,
inhibitors (caspase 6 inhibitor; 25M, BACE inhibitor; 10M) and APP-
blocking antibody (anti-APP; 20 g/ml, Fisher Scientific) were added to
the medium at the time of NGF withdrawal and axotomy or vincristine
treatment.
Axotomy and vincristine treatment. Axons were severed by a micro-
scalpel (Fine Science Tools) afterDIV5. Vincristinewas added afterDIV5
at a concentration of 0.04 M in NGF-supplemented medium.
Lentiviral infection of DRG neurons. For infection of DRG neurons,
lentivirus (105–106 infectious units) was added at DIV1 and 4 d later (to
allow for adequate transgene expression) experiments were performed.
Viral infection and transgene expression were examined via fluorescent
microscopy of the EGFP or mCherry reporter.
Dctn1 siRNA studies. DRG neurons (DIV1) were infected with
lentivirus-expressing Dctn1 or Luciferase siRNAs. To test the effects of
Bcl-xl and cytNmnat1 overexpression, cells were simultaneously infected
with lentiviruses expressing Dctn1 siRNA, along with viruses expressing
Bcl-xl or cytNmnat1. After infection, cultures were maintained for an
additional 7 d in the presence of 50 ng/mlNGF. Tomonitor neuronal cell
death, ethidium homodimer (100 nM final) was added, cells were fixed
after 30min, and fluorescent (dead)DRGneurons were counted. Axonal
degeneration was assessed as described below.
NGF internalization assay. Lyophilized NGF was fluorescently labeled
using a Cy3 labeling kit as per manufacturer’s instructions (GE Health-
care Biosciences). DRG neurons were plated in the inner chamber of
compartmentalized chambers, maintained for 14 d, and then infected
with lentiviruses expressing eitherDctn1 or Luciferase siRNA. Seven days
postinfection NGF was removed from both the inner (cell body) and the
outer (axonal) chambers and the neurons were incubated overnight in
Figure 2. Loss of axonal sAPP is not involved in axonal degeneration induced by mechanical or toxin damage. A–C, Immunofluorescent microscopic analysis using an antibody to the APP N
terminus to examine the “patchy” loss of surface APP (sAPP) on axons of neurons deprived of NGF (A), following axotomy (B), or treated with vincristine (C). Note the loss of sAPP following NGF
withdrawal but not aftermechanical or toxic insults, and that the loss of sAPP after NGFwithdrawal persists despite the expression of cytNmnat1 or Bcl-xl. Quantification of the percentage of axons
with decreased sAPP is displayed for each condition (see Materials and Methods). D, Conditioned medium was subjected to Western blot analysis for cleaved N-terminal APP fragment using
anti-N-APP antibody. The presence of shed N-terminal APP fragments was detected after NGF deprivation even under conditions where the axons were protected due to overexpression of Bcl-xl or
cytNmnat1. Significantly different (*p 0.001, Student’s t test) from neurons grown in the presence of NGF.
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medium lacking NGF. Cy3-NGF (100 ng/ml final) was added to the
axonal compartment and incubated at 37°C for 4 h. The percentage of
Cy3-positive neurons (indicating internalized NGF) was determined us-
ing fluorescence microscopy.
Immunohistochemistry. After fixation, cells were washed with PBS and
blocked with 4% normal donkey serum in TBST (Tris-buffered saline
plus 0.1% Triton X-100) (1 h, 37°C). Cells were incubated in primary
antibody (4°C overnight) and antibody binding was visualized with Al-
exa Fluor 488- or 594-conjugated anti-mouse and anti-rabbit secondary
antibodies (25°C, 1 h). To visualize APP on the axonal surface, cells were
incubated with MAB348 (1:100) without permeabilization. Cells were
incubated in primary antibody (4°C overnight) and antibody binding
was visualized with Alexa Fluor 594-conjugated anti-mouse secondary
antibody (25°C, 1 h). For quantification of sAPP loss, axons showing at
least four patches of decreased staining (i.e., areas of sAPP loss) were
counted from 4 random fields for each condition. Each experiment was
repeated three times and the percentage of axons bearing4 patches of
APP loss was determined.
Quantification of axonal degeneration. Axonal degeneration was quan-
tified as described previously (Sasaki et al., 2009a). Briefly, after axonal
severing, phase contrast images were taken using an invertedmicroscope
with a 20 objective (Eclipse TE 300; Nikon). MetaMorph software
(Molecular Devices) was used to image 3–4 random fields of distal axons
from each well with 40 ms exposure time by using CCD camera (Cool
SNAPES;Nikon). After brightness and background intensity adjustment
by the auto-level function in Adobe Photoshop, images were analyzed by
NIH ImageJ. The total axonal areawas determined by the total number of
detected pixels after binarization of the image. Nondegenerated axons
showed continuous tracts, while degenerating axons were fragmented,
beaded and showed up as aggregates. Degenerated axons were detected
using the particle analyzer of ImageJ as small particles, while healthy
axonal areas were represented as large continuous areas. The degenera-
tion index is the ratio of fragmented axon area to total axon area. Sixteen
fields were evaluated for each condition and each experiment was re-
peated three times.
Results
N-terminal APP fragmentation is not a universal initiator of
axon degeneration
To test the generality of the APP/caspase 6 pathway for axon
degeneration, we used three distinct triggers of axonal degenera-
tion in dorsal root ganglion (DRG) and superior cervical gan-
glion (SCG) neurons: NGF withdrawal, axotomy, and treatment
with the chemotherapeutic agent vincristine. If cleavage of APP is
the initial trigger for axonal degeneration, then blocking APP
cleavage with a BACE inhibitor or using anti-APP antibodies to
block its interaction with DR6 should block axonal degeneration
initiated by each of these insults. We treated DIV5 neurons with
theBACE inhibitorOM99-2 (10M)or anti-N-terminal amyloid
precursor protein (N-APP) antibody (20 g/ml) at the time of
axonal injury. Axonal degeneration was monitored over 24 h
using phase-contrast microscopy and a degeneration index
(D. I.) was calculated (see Materials and Methods). Axonal de-
generation increases dramatically after NGF deprivation (Fig. 1B;
supplemental Fig. S1, available at www.jneurosci.org as supple-
mental material). Consistent with previous findings, inhibiting
APP cleavage with a BACE inhibitor or a function-blocking an-
tibody against the shed N-APP fragment blocked axonal degen-
eration triggered by NGF withdrawal (Fig. 1A,B; supplemental
Fig. S1, available at www.jneurosci.org as supplemental material)
(Nikolaev et al., 2009). In contrast, neither the BACE inhibitor
nor the N-APP function-blocking antibody protected axons fol-
lowing axotomy or vincristine treatment (Fig. 1A,C,D; supple-
mental Fig. S1, available at www.jneurosci.org as supplemental
material). Hence, APP shedding is necessary for axonal degener-
ation following trophic factor withdrawal but not for degenera-
tion induced by mechanical or chemical insults.
Apoptotic pathways are not involved in axonal degeneration
caused by traumatic or toxin damage
While APP may be unnecessary for axonal degeneration fol-
lowing mechanical and neurotoxic insults, apoptotic path-
ways involving activation of caspase 6 may still be a common
downstream effector of diverse stimulus-dependent degenera-
tion pathways. We used two methods to test the role of caspase 6
in axonal degeneration. First, we used Bcl-xl overexpression to
block activation of the mitochondrial apoptotic signaling path-
way because it is downstream of N-APP-stimulated activation of
the DR6 receptor. Second, we evaluated the pharmacological in-
hibition of caspase 6. We also tested the effects of overexpression
of cytNmnat1, a cytosolic mutant of Nmnat1 (nicotinamide
mononucleotide adenylyltransferase 1) that provides robust ax-
onal protection after axotomy (Sasaki et al., 2006).We found that
axonal degeneration following NGF withdrawal is blocked by
Bcl-xl, cytNmnat1 or caspase 6 inhibitors (Fig. 1A,B; supplemen-
tal Fig. S1, available at www.jneurosci.org as supplemental mate-
Figure 3. Nmnat1 protects axons in the presence of activated caspase 6 and axonal degeneration induced by axotomy and vincristine does not involve caspase 6 activation. Immunofluorescence
detection of cleaved caspase 6 in SCG axons (top, microtubule staining; bottom, cleaved caspase 6 staining) reveals that caspase 6 is activated within 20 h after NGF deprivation. The activation of
caspase 6 is blocked by expression of Bcl-xl but not by the expression of cytNmnat1, despite the fact that cytNmnat1 effectively prevents axonal fragmentation after NGF withdrawal. Immunoflu-
orescence analysis of cleaved caspase 6 in SCG neurons revealed that caspase 6 is not activated after axotomy or vincristine treatment.
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rial), although the protection afforded by caspase 6 inhibition
was for a shorter time even with repeated daily additions of the
inhibitor (supplemental Fig. S2, available at www.jneurosci.org
as supplemental material, data not shown). In contrast to the
protection by cytNmnat1, axonal destruction initiated by axo-
tomy or vincristine intoxication was not affected by caspase 6
inhibition or Bcl-xl overexpression (Fig. 1A,C,D). These experi-
ments demonstrate that loss of axonal sAPP, stimulation of apo-
ptotic signaling, and caspase 6 activation are not involved in
axonal degeneration caused by mechanical or toxic insults and
imply that multiple pathways are involved in triggering axonal
degeneration.
While the APP/caspase pathway is selectively involved follow-
ing trophic factor withdrawal, there are also likely to be shared
components in the pathways leading to axonal degeneration. For
example, Wlds and its functional component Nmnat effectively
block axonal degeneration caused by both mechanical and
chemical injuries and Wld s preserves NGF-deprived axons
(Deckwerth and Johnson, 1994; Mack et al., 2001; Araki et al.,
2004; Sasaki et al., 2006, 2009a,b), suggesting these injuries acti-
vate a common downstream axonal execution pathway. To test
this hypothesis we overexpressed a cytoplasmically targeted vari-
ant of Nmnat, cytNmnat1, that provides robust axonal protec-
tion (Sasaki et al., 2009b), in SCG neurons. In the presence of
cytNmnat1, axons are robustly protected fromdegeneration after
NGF deprivation, axotomy and vincristine treatment (Fig. 1A–
C). As previously reported forwlds SCGneurons (Deckwerth and
Johnson, 1994), cytNmnat1 preserved both axonal integrity and
metabolic activity after NGF deprivation (supplemental Fig. S3,
available at www.jneurosci.org as supplemental material). These
Figure4. Bcl-xl inhibits both axonal and somal degeneration after NGF deprivationwhereas
cytNmnat1 specifically inhibits axon degeneration. A, Phase contrast microscopy of DRG soma
cultured in the presence of NGF or 72 h after NGF deprivation. In the absence of NGF, extensive
cell soma degeneration was observed in control (NGF) and cytNmnat1-expressing neurons
(NGF/cytNmnat1). In contrast, Bcl-xl-expressing neuronal soma (NGF/Bcl-xl) remained
refractile (alive) butwere smaller thanneurons grown inNGF.B, Quantitative analysis of refrac-
tile soma after NGF deprivation showed that most soma (90%) degenerated 72 h after NGF
withdrawal in control, cytNmnat1-expressing, and caspase 6 inhibitor (caspase 6i)-treatedDRG
neurons. The majority (68%) of Bcl-xl-expressing neuronal soma remained intact at 72 h after
NGF deprivation. Significantly different (*p 0.001, Student’s t test) from control neurons
after NGF withdrawal. C, Quantification of activated caspase 3-positive neurons demonstrated
that neither caspase 6 inhibitors nor cytNmnat1 expression blocked caspase 3 activation in the
cell soma; however Bcl-xl expression completely blocked caspase 3 activation after NGF depri-
vation. Significantly different (*p 0.001, Student’s t test) from neurons supplemented with
NGF. A total of 1100neurons fromeach conditionwere counted andexperimentswere repeated
3 times.
Figure 5. Neurturin deprivation results in loss of surface N-terminal APP and caspase 6
activation.A, Immunofluorescentmicroscopic analysis using an antibody to theAPPN terminus
demonstrated the patchy loss of surface APP (sAPP) on axons of SCG neurons deprived of Neur-
turin. B, Active caspase 6 was detected in SCG axons via visualization with carboxyfluorescein
within 20 h after Neurturin withdrawal. C, Quantitative analysis of axonal degeneration in SCG
neurons deprived of Neurturin. Note that treatment with caspase 6 inhibitor (VEID-CHO) or
expression of Bcl-xl or cytNmnat1 protects against axonal degeneration induced by Neurturin
withdrawal. *Significantly different (p 0.001, Student’s t test) from neurons grown in the
presence of Neurturin.
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findings suggest that Nmnat-mediated
axonal protection occurs via the inhibi-
tion of a common axon degeneration
pathway.
cytNmnat1 does not block loss of
axonal sAPP or caspase 6 activation
after NGF withdrawal
Axonal degeneration afterNGFdeprivation
requires APP cleavage, N-APP fragment in-
duced downstream signaling through the
DR6 receptor, and subsequent caspase 6 ac-
tivation (Nikolaev et al., 2009). We there-
fore investigated whether N-APP shedding
occurs in response to other axonal degener-
ation insultsbyexamining the surface lossof
APPon axons after axotomy and vincristine
treatment. As previously reported (Nikolaev
et al., 2009), NGF depletion induces the
loss of axonal surface immunoreactivity
for N-APP in patches (Fig. 2A); however,
surface APP was not lost when axonal de-
generation was induced by axotomy or
vincristine (Fig. 2B,C). These results are
consistent with the lack of axonal protec-
tion by N-APP-blocking antibodies or
BACE inhibitors after mechanical or
chemical injury (Fig. 1).
Caspase 6 activation is downstream of
N-APP generation (Nikolaev et al., 2009)
and caspase 6 inhibition effectively blocks
axonal degeneration after NGF with-
drawal. While caspase 6 inhibitors are
ineffective in preserving axons after me-
chanical or chemical injury, caspase 6
activation could be one of several inde-
pendent mechanisms that drive axonal
degeneration induced by these insults.We
stained for activated caspase 6 after injury, andwhile we observed
a punctate staining pattern of activated caspase 6 in NGF-
deprived axons, we did not detect caspase 6 activation after axo-
tomy or vincristine treatment (Fig. 3). Together, these results
lead us to conclude that loss of surface APP and caspase 6
activation play essential roles in axonal demise induced by
NGF withdrawal but that it is not involved in mechanical or
toxin-mediated axonal damage.
The preservation of NGF-deprived axons by cytNmnat1 pro-
vided an opportunity to investigate where Nmnat functions to
protect axons doomed by activation of the APP/caspase 6 path-
way. We first determined whether surface APP loss in SCG neu-
rons expressing either cytNmnat1 or Bcl-xl occurred after NGF
withdrawal. Even though bothmolecules provided robust axonal
protection, neither protein blocked axonal sAPP loss as deter-
mined by immunostaining (Fig. 2A) or Western blot analysis of
the conditioned media (Fig. 2D), indicating that they both func-
tion downstream of N-APP generation. Next, we examined the
effects of cytNmnat1 and Bcl-xl overexpression on caspase 6 ac-
tivation in NGF-deprived axons. We observed robust axonal
caspase 6 activation in control neurons, but not in those express-
ing Bcl-xl, indicating that the apoptotic cascade was blocked as
expected (Fig. 3). Surprisingly, cytNmnat1 did not block activa-
tion of caspase 6 despite the robust protection of these axons (Fig.
3). These results demonstrate that Nmnat exerts its axonal pro-
tective effects at a step that lies downstream (or parallel) to the
loss of axonal sAPP and caspase 6 activation invoked by
NGF-deprivation.
Nmnat-mediated protection is restricted to axons
Along with axonal degeneration, NGF withdrawal causes exten-
sive cell death. Interestingly, neurons from transgenic mice over-
expressing Bcl-2 are protected from both axon and cell soma loss
after NGF deprivation (Greenlund et al., 1995). Since both
Nmnat1 and Bcl-xl protect axons from degeneration after tro-
phic factor withdrawal, we investigated whether cytNmnat1 and
Bcl-xl can also protect against NGF-deprived neuronal death.
Cell death was monitored by phase-contrast microscopy (Fig. 4)
and ethidium homodimer uptake (supplemental Fig. S4, avail-
able at www.jneurosci.org as supplemental material). The per-
centage of dead neurons increased until essentially all soma were
degenerated (neuronal death) by 72 h after NGF-deprivation.
Neurons expressing Bcl-xl showed minimal somal or axonal de-
generation; however, cell size was remarkably smaller than those
maintained with NGF (Fig. 4A; supplemental Fig. S5, available at
www.jneurosci.org as supplemental material). In contrast, neu-
rons expressing cytNmnat1 had somal degeneration similar to
control neurons despite robust axonal protection. Further inves-
tigation revealed that soma degeneration followed a similar time
course in control and cytNmnat1-expressing neurons with 47
Figure 6. Apoptotic pathways play important roles in axonal degeneration and cell death caused by Dctn1 knock down. A,
Phase contrast microscopy showing axonal degeneration 7 d after DRG neurons were infected with lentiviruses expressing Lucif-
erase (Luc) or Dctn1 siRNA. Extensive axonal degeneration occurred after Dctn1 knockdown that was blocked by Bcl-xl expression,
caspase 6 inhibitor (caspase 6i) treatment, or cytNmnat1 expression. Axons of Luciferase siRNA-expressing neurons remained
intact. B, Ethidium homodimer staining overlying phase contrast images of DRG neurons show extensive cell death in Dctn1
knockdown neurons compared with those expressing Luciferase siRNA. Bcl-xl expression blocked cell death after Dctn1 knock-
down; however cytNmnat1 expression or caspase 6 inhibition failed to block neuronal death. C, Quantitative analysis of axonal
degeneration (i.e., degeneration index) displayed in A demonstrated the protection afforded by Bcl-xl, caspase 6 inhibitor and
cytNmnat1. D, Quantification of ethidium homodimer-positive neurons showed that only Bcl-xl expression blocks neuronal cell
death caused by Dctn1 knockdown. The number of dead DRG neurons in each condition was scored and the percentage of dead
neurons is displayed. Significantly different (*p 0.001, Student’s t test) from neurons expressing Luciferase siRNA.
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8% of control and 54 13% of Nmnat-expressing neuronal cell
bodies remaining refractile and excluding ethidium homodimers
(intact) after 24 h and only 3% at 72 h after NGFwithdrawal (Fig.
4B; supplemental Fig. S4, available at www.jneurosci.org as sup-
plemental material). In contrast, the cell bodies of neurons ex-
pressing Bcl-xl were protected from degeneration with 68.7 
6.8% of cell bodies excluding ethidium homodimer after 72 h of
NGF withdrawal (Fig. 4B; supplemental Fig. S4, available at
www.jneurosci.org as supplemental material).
We further investigated the mechanism of cell soma protec-
tion by examining caspase 3 activation, amarker of apoptotic cell
death.Within 24 h after NGFwithdrawal, activated caspase 3 was
detected using cleaved caspase 3-specific antibody in control
neurons, those treated with a caspase 6 inhibitor, and neurons
expressing cytNmnat1. However, no activated caspase 3 was de-
tected in neurons expressing Bcl-xl (Fig. 4C). Bcl-xl protects both
the axon and cell body by inhibiting activation of caspases,
whereas Nmnat mediates only axonal protection via a mecha-
nism that is independent of caspase activation.
To investigate whether the APP/DR6/caspase 6 pathway is
specific for neurotrophins that signal through Trk receptors or is
amore general phenomenon linked to loss of trophic support, we
examined the responses of SCG neurons to Neurturin depriva-
tion. We chose to examine Neurturin because it also supports
SCG neuron growth and survival (Kotzbauer et al., 1996) as it
signals through a different receptor, namely a receptor complex
containing the Ret tyrosine kinase receptor (Baloh et al., 2000).
SCG neuronal cultures were established in NGF and then
switched to Neurturin. After growing for 3 d in Neurturin, Neur-
turin was withdrawn and neuronal death and axonal degenera-
tionwere examined.We found thatNeurturinwithdrawal caused
loss of surface APP (Fig. 5A) (patchy APP staining was observed
in only 6  2% axons in control vs 87  6% after Neurturin
deprivation). Similar to the effects ofNGFwithdrawal, Neurturin
deprivation caused caspase 6 activation in axons (Fig. 5B). In
addition, inhibition of caspase 6 as well as overexpression of cyt-
Nmnat1 or Bcl-xl blocked axon degeneration induced by Neur-
turin deprivation (Fig. 5C). These results indicate that caspase 6 is
an important driver of axon degeneration resulting from with-
drawal of different classes of neurotrophic factors acting through
unique receptors.
Axonal degeneration caused by Dctn1 dysfunction can be
inhibited by Nmnat or caspase 6 inhibition
The APP/DR6/caspase 6 signaling pathway plays an important
role in NGF deprivation-mediated axonal degeneration. Muta-
tions that disrupt retrograde axonal transport are often associ-
ated with neurological disorders in which axonal degeneration is
an important component. Dctn1 is a component of the dynactin
complex that associates with dynein to drive retrograde axonal
transport of multiple cargoes along the microtubule lattice
(LaMonte et al., 2002; Schroer, 2004). Mutations in DCTN1 are
associated with motor neuron degenerative disorders, ALS asso-
ciated with frontotemporal dementia (FTD), and Perry syn-
drome, which has symptoms of Parkinsonism (Puls et al., 2003,
2005; Mu¨nch et al., 2004, 2005; Wider andWszolek, 2008; Farrer
et al., 2009; Vilarin˜o-Gu¨ell et al., 2009). These mutations impair
the transport of trophic factor back to the neuronal cell body
(Laird et al., 2008), leading to speculation that neurodegenera-
tion in these patients is due to lack of trophic factors in the soma
(Puls et al., 2005).
Disruption of dynein function leads to decreased NGF trans-
port and increased death in cultured DRG neurons (Wu et al.,
2007). We therefore tested whether depletion of Dctn1 induces
axonal degeneration via activation of the APP/DR6/caspase 6
pathway. DRG neurons were infected with lentiviruses express-
ing Dctn1 siRNA constructs. We constructed many and exten-
sively used three different Dctn1 siRNAs in these studies. The
efficiency of knockdown for these three siRNAs was quantified
using real-time RT-PCR analysis. We found that Dctn1–1 and
Dctn1-2 siRNAs reduced Dctn1 mRNA levels by 96% and 90%,
respectively; whereas Dctn-3 siRNA resulted in only a 15% re-
duction inDctn1mRNA(supplemental Fig. S6, available atwww.
jneurosci.org as supplemental material). DRG neurons were
infected with lentiviruses expressing each of these siRNAs con-
structs a timewhen they are critically dependent onNGF (DIV1).
DRG neurons infected with Dctn1-1 or Dctn-2 siRNA showed
extensive axon and soma degeneration, whereas those infected
with Dctn1-3 siRNA were indistinguishable from neurons ex-
pressing a Luciferase siRNA (Fig. 6A–D). Bcl-xl overexpression
blocked both axonal and somal degeneration (Fig. 6A–D),
whereas cytNmnat1 blocked only axonal degeneration in Dctn1-
deficient neurons. These results were similar to those obtained
with neurons after NGF withdrawal, suggesting that the mech-
Figure 7. NGF internalization is blocked by Dctn 1 knockdown. A, Fluorescentmicroscopy of
NGF trafficking using Cy3 labeled NGF. DRG neurons (DIV14) were infected with lentiviruses
expressing either Luciferase (Luc) or Dctn1 siRNA for 7 d. Neuronswere deprived of NGF for 16 h
then Cy3 labeled NGFwas added to themedium. After 4 h, Cy3 labeled NGF appeared in the cell
bodies of control neurons (Luc siRNA); however, no Cy3NGFwas observed in the neuronal soma
after Dctn1 knockdown (Dctn1 siRNA). B, The percentage of neurons containing Cy3-labeled
NGF in the cell body was determined. Note the normal level of internalized NGF in neurons
expressing Dctn1-3 siRNA that produces poor knockdown and no axonal degeneration. A total
of 400 neurons were analyzed and the experiments were repeated 3 times. Significantly differ-
ent (*p 0.001, Student’s t test) from Luciferase siRNA infected neurons.
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anism of neuronal damage caused by
Dctn1 knockdown and trophic factor
deprivation is similar.
To assess whether degeneration in-
duced by Dctn1 knockdown is due to
NGF transport deficits, wemeasuredNGF
internalization (see Materials and Meth-
ods) and found that depletion of Dctn1
decreases the amount ofNGF that is inter-
nalized (Fig. 7A,B). Indeed, the magni-
tude of the NGF transport defect with
each Dctn siRNA was directly correlated
with the amount of Dctn1 knockdown
and the extent of axon and soma damage.
The axonal degeneration, along with the
NGF trafficking defects, observed in neu-
rons deficient in Dctn1 prompted us to
examine the APP/DR6/caspase 6 pathway
in these neurons.We found that, likeNGF
withdrawal, Dctn1 knockdown initiated
loss of surface APP that could be blocked
by BACE inhibition (Fig. 8A,B). How-
ever, in contrast to axon degeneration
after NGF withdrawal, BACE inhibition
or APP-blocking antibody did not block
Dctn1-induced axonal degeneration (Fig.
8C).This isparticularly intriguingascaspase
6 inhibitionwas effective in blocking axonal
degeneration in Dctn1-deficient neurons.
Moreover, Bcl-xl overexpression blocked
both axon degeneration and cell death in
this paradigm (Fig. 6). The surprising di-
chotomy between blockade of APP surface
loss andcaspase6 inhibitionpromptedus to
examine caspase 6 activation in neurons ex-
pressing Dctn1 siRNA. We found that
caspase 6 was activated in neurons lacking
Dctn1 even in the presence of BACE inhib-
itors (Fig. 8D), indicating that caspase 6 can
be activated independently of APP cleavage.
Together, these results suggest that deficits
in axonal transport cause axonal degenera-
tion via mechanisms that are similar to
those invoked by trophic factor deprivation
as they both involve caspase 6 activation.
However, since caspase 6 is activated inde-
pendent of loss of surface APP in Dctn-
deficient neurons, it appears that multiple
pathways are capable of activating this en-
zyme and inducing axonal degeneration.
Discussion
Axonal degeneration is a hallmark ofmany debilitating neurolog-
ical disorders. Identifying themechanisms that drive such degen-
eration may lead to treatments that block or delay axon loss. The
recent identification of the APP/DR6/caspase 6 pathway (Niko-
laev et al., 2009) was a benchmark in the field because it suggested
rational targets for novel therapeutic interventions. Because this
pathway is well defined, it provided an opportunity to examine
whether it represents a common mechanism, activated in re-
sponse to multiple insults, to promote axonal degeneration. We
inhibited this pathway at multiple levels: APP cleavage, APP
function, apoptotic pathway activation, or caspase 6 activation;
and discovered that while each of these manipulations block ax-
onal degeneration following trophic factor withdrawal (NGF or
Neurturin), none of them provide axonal protection following
axotomy or vincristine treatment. This implies that multiple
stimulus-dependent pathways can invoke the cascade of events
required to bring about axon demise.
Apoptotic pathways appear to play important roles in axonal
degeneration triggered by trophic factorwithdrawal (e.g., NGFor
Neurturin). This is supported by our observation that Bcl-xl
blocks caspase 6 activation and axonal degeneration in neurons
deprived of trophic support. NGF deprivation stimulates parallel
Figure 8. APP-regulated pathways are not involved in axonal degeneration or caspase 6 activation in Dctn1 deficient neurons. A,
Immunofluorescentmicroscopic analysis using an antibody to theAPPN terminus demonstrated the characteristic patchy loss of sAPP on
axons fromneurons expressing Dctn1 siRNA. Compare to the continuous staining observed on axons fromneurons expressing Luciferase
(Luc) siRNA.TheDctn1siRNA-induced lossof sAPPwasblockedby treatmentwithBACE inhibitor (BACEi;OM99-2).B,Quantificationof the
percentage of axons with decreased sAPP is displayed for each condition (seeMaterials andMethods). Significantly different fromDctn1
siRNA-expressing neurons (**p 0.001). C, Axonal degeneration after Dctn1 knockdownwas not blocked by BACE inhibition or anti-N-
terminalAPP-blockingantibody(abN-APP).SignificantlydifferentfromLuciferasesiRNA-expressingneurons(*p0.001).D,Fluorescent
microscopicanalysisofcaspase6activation inaxonswasperformedusingDRGneurons infectedwith lentivirusexpressingeitherLuciferase
(Luc) siRNAorDctn1siRNA.Activationofcaspase6wasdetected inDctn1siRNA-expressingDRGneurons (Dctn1siRNA)usingcarboxyfluo-
rescein visualization. No caspase 6 activity (fluorescence) was observed in Luciferase siRNA-expressing axons. Dctn1 knockdown induced
strong fluorescence indicating caspase 6 activation. Inhibition of APP cleavagebyBACE inhibitor did not block activation of caspase 6 after
Dctn1 knockdown.
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pathways to induce the apoptotic process and caspase activation.
One is dependent on Bim induction and is responsible for Bax
translocation to mitochondria, whereas the other involves acti-
vation of Jnk pathways (Putcha et al., 2001). Moreover, NGF
deprivation activates glycogen synthase kinase 3 (GSK3) at the
axon tip, which initiates an apoptotic signal that travels back to
the neuronal cell body to induce Jun-mediated neuronal apopto-
sis (Mok et al., 2009). Another GSK3-mediated process that pro-
motes apoptosis is the phosphorylation of Bax and its subsequent
translocation into mitochondria (Linseman et al., 2004). Axonal
retrograde death-promoting signals that lead to apoptotic path-
way activation have also been observed in mouse models of ALS
(Perlson et al., 2009). While blocking APP cleavage is clearly
sufficient to suppress axonal degeneration after trophic factor
deprivation, the mechanism of apoptotic pathway activation
downstream of APP cleavage remains to be elucidated.
APP cleavage and activation of apoptotic pathways occurs
after loss of BDNF, NT3, and NGF-mediated Trk receptor
activation (Nikolaev et al., 2009).We found that withdrawal of
Neurturin, which signals through the Ret receptor tyrosine ki-
nase, also stimulated APP/caspase6 axon degeneration signaling
events. The difference between Trk and Ret mediated signaling is
substantial (Klesse and Parada, 1999; Airaksinen and Saarma,
2002; Huang and Reichardt, 2003), yet the loss of signaling after
NGF or Neurturin deprivation appears to stimulate common
axonal degeneration signals. These results suggest that common
adaptor molecules downstream of Trk and Ret receptors (e.g.,
Shc, GRB2, or PI3 kinase) may play key roles in the regulation of
APP processing and axon stability.
The dynein/dynactin1 complex facilitates retrograde axonal
transport of signaling molecules, including neurotrophins, from
the periphery back to the cell body. Mutations in dynactin 1
(DCTN1) are linked to a number of slowly progressing neurolog-
ical disorders (Puls et al., 2003, 2005; Mu¨nch et al., 2004, 2005;
Wider and Wszolek, 2008; Farrer et al., 2009; Vilarin˜o-Gu¨ell et
al., 2009), and the neuronal damage in these disorders is specu-
lated to involve loss of trophic factor delivery to the neuronal cell
body.We found that loss of Dctn1 caused impairedNGF traffick-
ing, surface APP loss, and caspase 6 activation. Although caspase
6 inhibition blocked axonal degeneration caused byDctn1 deple-
tion, inhibition ofAPP cleavage by inhibiting BACEdid not block
the axonal degeneration or caspase 6 activation, suggesting that
caspase 6 activation inDctn1-depleted neurons is independent of
APP cleavage. This could occur due to impaired retrograde ax-
onal transport in Dctn1-depleted neurons as this would limit the
availability (at the neuronal cell body) of vital factors and signal-
ing molecules associated with signaling endosomes such as
P-Trk, Erk1/2 and Erk5 (Delcroix et al., 2003) to induce apopto-
tic pathway activation. Furthermore, Dctn1 interacts with Kine-
sin II to regulate transport of organelles including mitochondria
(Deacon et al., 2003). Dctn1 deficiency could therefore also dis-
rupt neuronal energy homeostasis, another potential mechanism
of caspase 6 activation.
While distinct, stimulus-dependent mechanisms trigger ax-
onal degeneration in response to trophic factor deprivation, me-
chanical injury, or chemical toxicity; each of these pathways is
blocked by expression of Nmnat1, a component of theWlds pro-
tein (Araki et al., 2004; Sasaki et al., 2006, 2009a,b; Yahata et al.,
2009). Nmnat is themost potent axonal protection factor known,
however, its mechanism of action remains obscure. The require-
ment for the APP/caspase 6 pathway for axonal degeneration
induced by trophic factor deprivation afforded an opportunity to
identify where in the cascade Nmnat is exerting its protective
effects. In neurons overexpressing cytNmnat1, NGF withdrawal
still leads to loss of axonal sAPP and activation of axonal caspase
6, yet axonal degeneration does not occur. These findings are
consistent with the prevention of degeneration in caspase-
positive dendrites byWlds protein inDrosophila (Schoenmann et
al., 2010). From these observations, three important aspects of
axonal degeneration emerge: (1) Nmnat influences a step down-
stream or parallel to caspase 6 activation; (2) caspase 6 activation
does not occur in all axonal injury paradigms; and (3) distinct,
injury-specific pathways of axonal degeneration must converge
on a common, Nmnat-sensitive axonal degeneration program.
Although cytNmnat1 protects axons from degeneration after
loss of trophic support or Dctn1 knockdown, it failed to protect
the cell soma. Our results and previous experiments indicate that
different signaling cascades are responsible for degeneration of
the axon and soma (Nikolaev et al., 2009). For example, after
NGF deprivation inhibitors of caspase 6 and caspase 3 selectively
inhibit axon or soma degeneration, respectively. Further work to
pinpoint the critical substrates of caspase 6 in axons, as well as the
steps in axonal degeneration that aremodulated byNmnatwill be
crucial if we are to exploit its potential for treating the axonopa-
thy accompanying neurological disorders.
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